Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Valdoxan, agomelatine (Thymanax) (AGO178)
print preview
bookmark
share with colleague
General Information
Company
Servier
Description
Melatonin MT1 and MT2 receptor agonist and serotonin (5-HT2C) receptor antagonist
Molecular Target
Melatonin MT1 receptor
;
Melatonin MT2 receptor
Mechanism of Action
Serotonin (5-HT2C) receptor antagonist; Melatonin MT2 receptor agonist
Latest Stage of Development
Marketed
Indication
Depression
Partner
Novartis AG
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy